Llibre Josep M, Domingo Pere, del Pozo Miguel A, Miralles Celia, Galindo Maria J, Viciana Isabel, Moreno Santiago, Schapiro Jonathan M, Clotet Bonaventura
Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
J Antimicrob Chemother. 2008 Jan;61(1):206-9. doi: 10.1093/jac/dkm438. Epub 2007 Nov 13.
To determine the feasibility and outcomes of long-distance interactive expert advice for treatment-experienced patients.
HIV-1-infected patients on failing highly active antiretroviral therapy (HAART) were prospectively submitted for consultation by treating physicians to an expert panel using a standard e-mail form including: resistance tests, antiretroviral history, adherence, CD4 counts, HIV-1-RNA levels and HCV/HBV co-infection. Conference calls (CCs) were scheduled monthly to discuss 10 new patients.
One hundred and fifteen patients were discussed (86% male; 45% intravenous drug users). The median length of HIV infection was 10 years and subjects were treated for a median of 8 years with a median of 5.25 previous HAART regimens. Ninety per cent were triple-class experienced [nucleoside reverse transcriptase inhibitors (NRTIs)/non-NRTIs (NNRTIs)/protease inhibitors (PIs)]. Median CD4 cell count was 298 cells/mm(3) and median viral load was 19 700 copies/mL. Overall, 60% had >or=5 reverse transcriptase mutations and 67% had >or=5 protease mutations, and most patients were NNRTI-resistant. Drugs more frequently recommended by experts were: lamivudine/emtricitabine > tenofovir > abacavir > zidovudine > didanosine > stavudine (NRTIs) and tipranavir > lopinavir > atazanavir > saquinavir (PIs). Enfuvirtide was recommended in 65% of cases. Concordance between recommended and prescribed regimens was 74.7%. Virtually all discordances were due to patient refusal of complex regimens. Outcomes at 24 weeks: HIV-1-RNA <50 copies/mL in 42% of patients, HIV-1-RNA <400 copies/mL in 59.4% of patients and median CD4 increase was 77 (14-140) cells/mm(3).
Long-distance interactive expert advice is feasible for complex treatment-experienced HIV patients using e-mail and CCs. Adherence to treatment recommendations is high, with encouraging viro-immunological outcomes at 24 weeks. This strategy merits further investigation, especially in clinical settings where availability of local experts is limited.
确定为有治疗经验的患者提供远程交互式专家建议的可行性和结果。
正在接受高效抗逆转录病毒治疗(HAART)但治疗失败的HIV-1感染患者,由治疗医生使用标准电子邮件表格将其提交给一个专家小组进行会诊,表格内容包括:耐药检测、抗逆转录病毒治疗史、依从性、CD4细胞计数、HIV-1-RNA水平以及HCV/HBV合并感染情况。每月安排电话会议(CCs)讨论10名新患者。
共讨论了115名患者(86%为男性;45%为静脉吸毒者)。HIV感染的中位时长为10年,患者接受治疗的中位时长为8年,之前接受过的HAART方案中位数为5.25种。90%的患者有三类药物治疗经验[核苷类逆转录酶抑制剂(NRTIs)/非核苷类逆转录酶抑制剂(NNRTIs)/蛋白酶抑制剂(PIs)]。CD4细胞计数中位数为298个细胞/mm³,病毒载量中位数为19700拷贝/mL。总体而言,60%的患者有≥5个逆转录酶突变,67%的患者有≥5个蛋白酶突变,且大多数患者对NNRTIs耐药。专家更常推荐的药物为:拉米夫定/恩曲他滨>替诺福韦>阿巴卡韦>齐多夫定>去羟肌苷>司他夫定(NRTIs)以及替拉那韦>洛匹那韦>阿扎那韦>沙奎那韦(PIs)。65%的病例中推荐了恩夫韦肽。推荐方案与处方方案之间的一致性为74.7%。几乎所有的不一致都是由于患者拒绝接受复杂方案。24周时的结果:42%的患者HIV-1-RNA<50拷贝/mL,59.4%的患者HIV-1-RNA<400拷贝/mL,CD4细胞计数中位数增加77(14 - 140)个细胞/mm³。
对于有复杂治疗经验的HIV患者,使用电子邮件和电话会议进行远程交互式专家建议是可行的。对治疗建议的依从性较高,24周时的病毒学和免疫学结果令人鼓舞。该策略值得进一步研究,尤其是在当地专家资源有限的临床环境中。